Horizon and Envigo complete transaction
On November 8, 2019, Envigo announced an agreement to acquire the research models business unit of Horizon Discovery Group (also called Horizon In Vivo). This Horizon business unit is one of the global leaders in the creation and supply of genetically modified research models. As President and CEO of Envigo, I’m excited to announce the acquisition is now complete. You can learn more about the transaction here.
We are committed to making the transition as smooth as possible for you. There are no changes to the way you work with the In Vivo business unit and your current contacts are the same as they were previously. I know that the In Vivo team is excited to become part of the Envigo portfolio and beginning to build more capabilities based on the breadth of their offering. Horizon and Envigo will continue to collaborate to support the delivery of future Horizon In Vitro services.
As a result of this transaction, Envigo is pleased to offer new services in four (4) key areas:
- Custom generation of genetically modified research models (gene deletions, insertions and other modifications)
- Catalog transgenic research models, including models for research in cancer, neuroscience and cardiovascular disease
- Support services, such as custom breeding, cryo-preservation and cryo-recovery
- Tumor model studies using patient-derived (PDX) tumor sources for breast cancer and melanoma
We hope you share our excitement in bringing these new, scientifically driven service offerings to our broad portfolio. And, as always, thank you for your continued business.
Adrian Hardy President and Chief Executive Officer Envigo